Dark

Check out our Level2View

ADXS
AYALA PHARMACEUTICALS INC
stock OTC

Inactive

Feb 3, 2026

0.6036USD+5.886%(+0.0336)13,591

Pre-market

0.00USD-100.000%(-0.57)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 28, 2022

08:00AM EST Advaxis Prices Offering of $5,000,000 of Convertible Redeemable GlobeNewswire Inc

Jan 11, 2022

08:10AM EST Advaxis Highlights Presentation Of Updated Clinical Data From Ongoing Phase 1/2 Trial Of ADXS-503 In NSCLC And Upcoming Milestones Benzinga

08:00AM EST Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 GlobeNewswire Inc

Dec 23, 2021

07:01AM EST OTC Markets Group Welcomes Advaxis, Inc. to OTCQX PR Newswire

Dec 22, 2021

04:05PM EST Advaxis Announces Acceptance for Trading on the OTCQX GlobeNewswire Inc

Dec 17, 2021

08:03AM EST Advaxis Reports Will Explore Added Options To Maximize Shareholder Value; Shareholders Approved Proposal 1, Reverse Split Proposal Not Approved Benzinga

08:00AM EST Advaxis to Continue to Explore Additional Options to Maximize GlobeNewswire Inc

Dec 9, 2021

08:00AM EST Stockholders passed Proposals 1 (the Merger) and 4 (Executive Compensation) GlobeNewswire Inc

Nov 24, 2021

08:06AM EST Advaxis Issues Letter, Second Video Message To Stockholders Regarding Upcoming Special Meeting Benzinga

08:00AM EST Company releases video message highlighting the need for all proposals to pass in order to consummate the proposed Biosight transaction GlobeNewswire Inc

Nov 23, 2021

06:39AM EST Advaxis Granted U.S. Patent #11,179,339 'Compositions and methods for lyophilization of bacteria or listeria strains' Benzinga

Nov 22, 2021

08:00AM EST Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to GlobeNewswire Inc

Nov 19, 2021

08:03AM EST Advaxis, Inc. Issues Letter to Stockholders Benzinga

08:00AM EST Advaxis, Inc.(Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today issued the following statement to stockholders: GlobeNewswire Inc

Nov 18, 2021

08:17AM EST Independent Proxy Advisory Firm Glass Lewis Joins ISS In Recommending Advaxis Stockholders Vote "FOR" Proposed Merger With Biosight Benzinga

08:00AM EST Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in GlobeNewswire Inc

Nov 12, 2021

05:48AM EST Top 10 WallStreetBets Stock Mentions In Pre-Market Session for Nov.12, 2021: SNDL, TSLA, GME, MSFT, NVDA, PLTR, PSFE, ADXS, AMC, WISH Benzinga

Nov 11, 2021

08:00AM EST Combined company, to be named Biosight Therapeutics, expected to be well-positioned to leverage its compelling oncology therapeutics pipeline, strong cash position, and accomplished management and Board to maximize stockholder value GlobeNewswire Inc

Nov 4, 2021

08:00AM EDT Company releases video message highlighting strategic rationale and benefits of proposed Biosight transaction for Advaxis stockholders GlobeNewswire Inc

Nov 3, 2021

08:00AM EDT Leading Independent Proxy Advisory Firm ISS Recommends Advaxis GlobeNewswire Inc

Sep 10, 2021

07:36PM EDT Advaxis Earnings Perspective: Return On Capital Employed Benzinga

08:32AM EDT Advaxis Q3 EPS $(0.02) Beats $(0.04) Estimate, Sales $250.00K Benzinga

08:30AM EDT Entered definitive merger agreement with Biosight Ltd. to advance pipeline of clinical-stage oncology programs for solid tumors and hematological malignancies GlobeNewswire Inc

Aug 25, 2021

05:28PM EDT Advaxis S-4 Filing Out Related To Proposed Merger Between Advaxis, Biosight Benzinga

Aug 11, 2021

08:00AM EDT Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to GlobeNewswire Inc

Jul 15, 2021

08:53AM EDT Advaxis Kick Starts Early-Stage Study For Prostate Cancer Immunotherapy Benzinga

08:06AM EDT Advaxis Announces Initiation Of Phase 1 Clinical Trial Of ADXS-504 For Treatment Of Early Prostate Cancer Benzinga

Jul 14, 2021

04:03PM EDT Advaxis to Present at the Non-Small Cell Lung Cancer Drug GlobeNewswire Inc

Jul 7, 2021

03:47PM EDT ADVAXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Advaxis, Inc. - ADXS Business Wire

Jul 6, 2021

02:54PM EDT Mid-Afternoon Market Update: Dow Tumbles 300 Points; Advaxis Shares Spike Higher Benzinga

12:08PM EDT Mid-Day Market Update: Gold Rises Over 1%; Provention Bio Shares Plunge Benzinga

09:02AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Jul. 6, 2021: CCXI, DIDI, AXP, ADXS, OGI Benzinga

08:09AM EDT Advaxis Stock Shoots Higher On Reverse Merger Agreement With Biosight Benzinga

06:04AM EDT Advaxis And Biosight Announce Entry Into Merger Agreement; Biosight Shareholders To Become Majority Shareholders Of Combined Co., Combined Co. To Have $50M In Cash, Cash Equivalents And Marketable Securities Benzinga

06:00AM EDT Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236)in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) GlobeNewswire Inc

Jun 14, 2021

04:06PM EDT Advaxis Q2 EPS $(0.04) Up From $(0.10) YoY, Sales $1.38M Up From $250.00K YoY Benzinga

04:05PM EDT ADXS-503 Phase 1/2 trial data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA GlobeNewswire Inc

May 19, 2021

05:03PM EDT Advaxis Highlights Presentation Of Updated Data From Ongoing Phase 1/2 Trial Of ADXS-503 In Non-Small Cell Lung Carcinoma At American Society Of Clinical Oncology: 'show disease control rate of 44% with durable clinical benefit observed beyond one year' Benzinga

05:01PM EDT Updated data show disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on pembrolizumab GlobeNewswire Inc

Apr 28, 2021

04:30PM EDT Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually, on June 4-8, 2021. GlobeNewswire Inc

Apr 26, 2021

11:07AM EDT Advaxis, Inc.(NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has achieved the second milestone under its licensing agreement for ADXS31-164, also known as ADXS-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans. GlobeNewswire Inc

08:15AM EDT Advaxis Reports Receipt Of Second Milestone Payment Under ADXS-HER2 License Deal With OS Therapies Benzinga

08:00AM EDT Advaxis, Inc.(NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has received the second milestone payment related to its licensing agreement for ADXS31-164, also known as ADXS-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans. GlobeNewswire Inc

Apr 12, 2021

08:40AM EDT Advaxis Announces $20M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Benzinga

08:30AM EDT Advaxis, Inc. Announces $20 Million Registered Direct Offering GlobeNewswire Inc

Apr 10, 2021

08:31AM EDT Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade GlobeNewswire Inc

Apr 5, 2021

08:04AM EDT Advaxis Announces Agreement With Columbia University Irving Medical Center To Fund Phase 1 Study Of ADXS-504 For Treatment Of Early Prostate Cancer; Funding Amount Not Disclosed Benzinga

08:00AM EDT Advaxis Announces Agreement with Columbia University Irving GlobeNewswire Inc

Mar 25, 2021

02:45PM EDT Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference Benzinga

Mar 23, 2021

07:12PM EDT Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021 Benzinga

11:34AM EDT Advaxis to Present Corporate Overview at the Benzinga Biotech GlobeNewswire Inc

Mar 16, 2021

09:02AM EDT Advaxis Q1 EPS $(0.05) Up From $(0.15) YoY, Sales $1.61M Up From $3.00K YoY Benzinga

09:00AM EDT Continued enrollment in expanded ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors GlobeNewswire Inc

Mar 12, 2021

08:00AM EST Advaxis to Present at the American Association for Cancer Research GlobeNewswire Inc

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Jan 26, 2021

02:27PM EST Advaxis Awarded U.S. Patent #10,900,044 'Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof' Benzinga

09:55AM EST Advaxis Granted U.S. Patent Titled 'Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof' Benzinga

Jan 25, 2021

07:07AM EST Advaxis Says SITC Presentation From Ongoing ADXS-503 Phase 1/2 Clinical Trial Demonstrated Disease Control Rate Of 67%, Overall Response Rate Of 17% In First Six Evaluable Patients With Immediate Prior Progression On KEYTRUDA Benzinga

07:00AM EST Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors GlobeNewswire Inc

Jan 19, 2021

08:22AM EST Advaxis Announces Receipt Of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement With OS Therapies; Terms Not Disclosed Benzinga

08:00AM EST Advaxis, Inc.(NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has received the first milestone payment related to its licensing agreement for ADXS31-164, now known as OST-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans. GlobeNewswire Inc

Dec 22, 2020

01:42PM EST Advaxis Announces Listing Transfer to Nasdaq Capital Market and GlobeNewswire Inc

Nov 27, 2020

12:07PM EST Advaxis, Inc. Announces Closing of $9.2 Million Public Offering GlobeNewswire Inc

Nov 25, 2020

07:35AM EST The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback Benzinga

Nov 24, 2020

02:30PM EST Mid-Afternoon Market Update: Dow Tops 30,000; Goldfield Shares Spike Higher Benzinga

12:05PM EST Mid-Day Market Update: Crude Oil Jumps Over 4%; Dycom Industries Shares Plummet Benzinga

08:37AM EST Advaxis Prices 26,666,666 Share Common Stock Offering At $0.30/Share Benzinga

08:30AM EST Advaxis, Inc. Announces Pricing of $8 Million Public Offering GlobeNewswire Inc

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 23, 2020

04:08PM EST Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock; Terms Not Disclosed Benzinga

04:05PM EST Advaxis, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

Nov 9, 2020

08:20AM EST Advaxis Presents Updated Data From Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial At The 2020 Society For Immunotherapy Of Cancer Annual Meeting Benzinga

08:01AM EST Disease control rate of 67% and overall response rate of 17% in first six evaluable patientswith immediate prior progression on KEYTRUDA GlobeNewswire Inc

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Oct 26, 2020

08:01AM EDT Advaxis' ADXS-503 Demonstrates Pronounced, Sustained Tumor Control In Ongoing Phase 1/2 Lung Cancer Trial Benzinga

08:00AM EDT Disease control rate of 67% in first six evaluable patients who had progressed on KEYTRUDA GlobeNewswire Inc

Oct 15, 2020

08:18AM EDT Advaxis To Present Data From Ongoing ADXS-503 Phase 1/2 Clinical Trial At SITC 2020 Benzinga

08:01AM EDT Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it will present an ePoster at the 35th Annual Meeting of the Society for Immunology of Cancer (SITC 2020) to be held virtually November 9-14, 2020. GlobeNewswire Inc

Sep 29, 2020

08:30AM EDT Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan GlobeNewswire Inc

Sep 24, 2020

11:14AM EDT Advaxis shares are trading higher after the company announced the FDA has cleared a new Investigational New Drug application for the initiation of an Investigator Sponsored Phase 1 clinical study of ADXS-504 for the treatment prostate cancer. Benzinga

08:19AM EDT Advaxis Announces FDA Clearance Of New IND For ADXS-504 For Treatment Of Prostate Cancer Benzinga

08:00AM EDT Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND GlobeNewswire Inc

Sep 10, 2020

08:14AM EDT Advaxis Q3 EPS $(0.09) Up From $(1.00) YoY Benzinga

08:00AM EDT Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors GlobeNewswire Inc

Sep 4, 2020

04:30PM EDT Advaxis Announces Resignation of Chief Financial Officer Benzinga

Aug 27, 2020

08:01AM EDT Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the LD Micro 500 Virtual Conference, being held virtually September 1 4, 2020. GlobeNewswire Inc

Aug 3, 2020

08:08AM EDT Advaxis Announces Common Stock Purchase Agreement For Up To $20M With Lincoln Park Capital, Which Bought $2M Shares At $0.57/Share Benzinga

08:00AM EDT Advaxis Announces Common Stock Purchase Agreement for up to $20 GlobeNewswire Inc

Share